CHARLOTTE, N.C., Feb. 7, 2008 (PRIME NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has initiated patient dosing in study 302, the first of two pivotal Phase III trials designed to demonstrate efficacy and support US marketing of approval of Droxidopa in neurogenic orthostatic hypotension (NOH).
